OPTUNE® TREATMENT FOR
GLIOBLASTOMA (GBM)
Intended for US healthcare professionals only.

Mechanism of action

Optune delivers TTFields to selectively disrupt mitosis1,2

  • TTFields are low-intensity (1-3 V/cm) alternating electric fields tuned to a specific frequency (for example, 200 kHz for GBM) to disrupt tumor cell division1
    • TTFields disrupt cell division through physical interaction with key molecules during multiple phases of mitosis1,2

TTFields target dividing cells, leading to apoptosis

Metaphase — uniform electric field
Tumor Treating Fields (TTFields) disrupt cancer cell division through physical interaction with molecules during phases of mitosis
  • Disrupt alignment of highly polarized tubulin subunits2
  • Disrupt microtubule spindle formation during mitosis and may ultimately lead to apoptosis2,3
Telophase — nonuniform electric field
Tumor Treating Fields (TTFields) disrupt cancer cell division through physical interaction with molecules during phases of mitosis
  • A change in cell shape during telophase causes a nonuniform electric field2,4
  • Polar cell components move toward cleavage furrow2
  • Cell cannot divide properly, which may ultimately lead to apoptosis2,3

Learn about TTFields mechanism of action

TTFields, Tumor Treating Fields.

References: 1. Optune. Instructions for Use for Glioblastoma Multiforme. Novocure; 2019. 2. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64(9):3288-3295. 3. Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5(1):1-16. 4. Gutin PH, Wong ET. Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality. Am Soc Clin Oncol Educ Book. 2012:126-131.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).